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ABSTRACT
Patient-derived tumor xenograft (PDX) mouse mod-
els are a versatile oncology research platform for
studying tumor biology and for testing chemother-
apeutic approaches tailored to genomic character-
istics of individual patients’ tumors. PDX models
are generated and distributed by a diverse group of
academic labs, multi-institution consortia and con-
tract research organizations. The distributed nature
of PDX repositories and the use of different meta-
data standards for describing model characteris-
tics presents a significant challenge to identifying
PDX models relevant to specific cancer research
questions. The Jackson Laboratory and EMBL-EBI
are addressing these challenges by co-developing
PDX Finder, a comprehensive open global catalog of
PDX models and their associated datasets. Within
PDX Finder, model attributes are harmonized and in-
tegrated using a previously developed community
minimal information standard to support consistent
searching across the originating resources. Links to
repositories are provided from the PDX Finder search
results to facilitate model acquisition and/or collab-
oration. The PDX Finder resource currently contains
information for 1985 PDX models of diverse can-
cers including those from large resources such as
the Patient-Derived Models Repository, PDXNet and
EurOPDX. Individuals or organizations that generate
and distribute PDXs are invited to increase the ‘find-
ability’ of their models by participating in the PDX
Finder initiative at www.pdxfinder.org.
INTRODUCTION
PDX models recapitulate many of the disease hallmarks
of cancer patients and are increasingly being used to study
therapeutics, tumor evolution and drug resistance mecha-
nisms. PDXmodels are typically generated by the implanta-
tion of human tumor tissues or cells into severely immunod-
eficientmouse host strains. Tumors that engraft successfully
are passaged further to generate cohorts of tumor-bearing
mice for experimental studies. PDX models are generated
and used by researchers in university, clinical and pharma-
ceutical industry settings as well as specialized commercial
organizations. International consortia focusing on the use
of PDXmodels including PDXNet and EurOPDX have re-
cently been funded ensuring PDX models will continue to
be an important contributor to understanding and treating
cancer.
The distributed and diverse nature of PDX repositories
as well as differences in associated metadata describing the
models presents a significant challenge to researchers seek-
ing to find PDXs that are relevant to specific cancer re-
search questions. To address this issue, The Jackson Labo-
ratory and the EuropeanMolecular Biological Laboratory-
European Bioinformatics Institute (EMBL-EBI) have im-
plemented PDXFinder (http://www.pdxfinder.org), a freely
available and searchable catalog of global PDX reposito-
ries. The data model for PDX Finder is based on the min-
imal information standard for PDX models developed in
collaboration with a broad range of stakeholders who cre-
ate and/or use PDXmodels in basic and pre-clinical cancer
research (1). PDX Finder currently provides access to in-
formation 1985 PDX models in 8 repositories around the
world, including NCI’s Patient Derived Model Repository,
The Jackson Laboratory’s PDX Resource, members of the
EurOPDX Consortium and members of NCI’s PDXNet.
Here we describe the implementation of PDX Finder and
illustrate how it can be used to locate relevant PDX mod-
els. We also provide information on how investigators with
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Figure 1. PDXModel Search page. Example of a search output corresponding to a query for colorectal cancer PDX model with KRAS G12D mutations
and resistance to cetuximab.
small or large repositories of PDX models can have their
resource indexed in PDX Finder to improve the visibility of
their models.
PDX FINDER FEATURES AND FUNCTIONALITY
To ensure PDX Finder reflects the diverse needs and goals
of researchers who use PDX models, we adopted a user-
centred design process. User-centred design involved stake-
holder and user interviews as well as workshops that al-
lowed us, in the early stage of the project, to identify and
characterize our main groups of users, suggest typical use
cases and identify priority requirements for the users. The
three priority features to emerge from the requirements
gathering process were:
1. Availability of high level summaries (graphical and tab-
ular) providing an overview of all the models and repos-
itories included in PDX Finder.
2. Search forms that allow researchers to find PDXmodels
based on diagnosis (e.g. colorectal cancer, invasive duc-
tal carcinoma), cancer type (e.g. metastasis or primary),
availability of specific datasets (e.g. mutation, dosing
studies), molecular markers (e.g. KRAS V600E) and re-
sults from drug resistance/sensitivity dosingmodel stud-
ies (e.g. resistance to cetuximab).
3. Summary pages for individual models with details about
how themodel was generated, de-identified patient infor-
mation, links to available data sets andmodel acquisition
information.
PDX Finder home page
The PDX Finder home page prominently features search
capabilities allowing users to perform a lexical search over a
number of categories and summary graphics of the resource.
In the Find section, users can search for patient diagnoses
to retrieve corresponding PDX models. In the Explore sec-
tion, we also offer different points of entry to the mod-
els, represented by lists and bar charts that group models
by ‘frequently mutated genes’, ‘drugs tested on PDX mod-
els’, ‘anatomical systems’ and individual providers. A ‘News
and Events’ section on the bottom of page provides head-
line summaries with links to news items about the PDX re-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/D
1/D
1073/5232437 by Jackson Laboratory user on 14 January 2019
Nucleic Acids Research, 2019, Vol. 47, Database issue D1075
source as well as a Twitter feed where users can stay up to
date with the latest developments to the resource. Finally,
the top menu bar provides details about the PDX Finder
project, including our information gathering process and
the submit/contact section that contains instructions on
how to submit PDX model data to the resource.
Search functions
Users navigate to the ‘Search Results’ page by searching for
a diagnosis in the search box or choosing a category from
one of the graphical visualizations. Results are presented in
a tabular format with each row depicting a model (Figure
1). Key features of the models are presented in columns and
include model ID and provider, tumor diagnosis, critical
patient tumor clinical data and links to available datasets.
Multiple filters provided on the leftmargin of the page allow
users to further specify themodels they would like to appear
in the results table. Filters are grouped within categories ac-
cording to PDX MI standard (1) and can be selected by
expanding a facet and further selecting one or more filters
in the relevant sub-categories. The search functionality al-
lows users to find the right model for their project and filter
accordingly with their own specific criteria. For example,
‘find all colorectal cancer models with KRAS G12D muta-
tion,’ will retrieve 68 models from two sources. Additional
filtering using drug dosing sensitivity or resistance will fur-
ther refine the search to make it more specific. ‘Find all col-
orectal cancer models with KRASG12Dmutations and re-
sistance to cetuximab’ will retrieve nine models from one
source (Figure 1). Additional filters allow selection of mod-
els linked to associated dataset types (genomic data, drug
dosing or patient treatment) or as derived from a specific
project (EurOPDX or PDXnet). For searches that return
multiple models, the results can be exported in a tabular for-
mat. Users can navigate to a model page or to the data of
interest by clicking on the unique PDX Model ID or data
links in each row.
Model, patient and data detail pages
The PDXModel Detail page (Figure 2A) presents key fea-
tures about the model. The top of the page displays the
model ID and tumor histological classification as well as
prominent links to the originating resource where users can
find more information and contact the relevant institution
for further collaboration. A tabulated section beneath the
overview provides summary views of the models with clin-
ical, model and validation information as well as views of
additional data thatmay have been submittedwith the PDX
model including gene variant data or results from drug dos-
ing studies.
The patient page (Figure 2B) displays information about
the patient and the tumor collection event(s) used in gen-
eration of the PDX model. Key clinical tumor characteris-
tics such as diagnosis, type (primary and metastatic), age
and collection site are presented here. When patients are
sampled at different times during their disease progression,
clickable links to PDX models allow users to easily browse
between these patient related models. Furthermore, details
about treatment the patient received are included when that
information is provided.
The molecular data page contains genomic data analy-
sis files that where provided by the resources. A table sum-
marises the types of data and files accessible through the
PDX Finder with links to external resources when avail-
able. Users can select a dataset to obtain a detailed view and
can search their gene of interest using available search boxes
(Figure 3A). Links to protocols and platforms description
are provided to allow the user to understand how the data
was generated and analysed.
The drug dosing page summarises the drug–response re-
sults generated for a particular model and provide links to
the procedure description used to generate the dosing stud-
ies (Figure 3B).
NOMENCLATURE AND METADATA STANDARDS
PDX Finder facilitates discovery of similar models across
resources by the use and enforcement of nomenclature and
metadata standards. Cancer type, diagnosis and other can-
cer attributes are represented by the NCI Thesaurus, a
terminology resource that is maintained by the NCI (2).
Names and symbols for human genes follow the nomen-
clature standards approved by the HUGO Gene Nomen-
clature Committee (3). Host mouse strain nomenclature
follows the official guidelines established by the Interna-
tional Committee on Standardized Genetic Nomenclature
for Mice (4). Drug/compound names use standards from
NCIT(2), CHEBI (5), CHEMBL (6) and PubChem (7). In
addition, we provide feedback to ontology developers to im-
prove these resources for representing the complexities of
PDX models.
DATABASE AND SOFTWARE INFRASTRUCTURE
The PDX Finder web site was implemented using a combi-
nation of the WordPress content management system and
a Java web application. The database for PDX Finder is
a Neo4J graph database. To populate this database, be-
spoke Extraction, Transformation, Loading (ETL) soft-
ware pipelines were written in Java to extract relevant at-
tributes corresponding to the PDX minimal information
standard from the data provided by the different PDX
repositories. Software developed by the PDX Finder team
is freely available under an Apache 2 license (https://www.
apache.org/licenses/LICENSE-2.0) and the PDX Finder
source code is available at GitHub (https://github.com/
pdxfinder).
A number of key attributes specified in the minimal infor-
mation standard rely on different vocabularies and ontolo-
gies. To address this challenging harmonization issue, PDX
Finder employs a semi-automated integration approach us-
ing resources at EMBL-EBI including the ZOOMA anno-
tation tool (8) that maps free text annotations to ontology
terms based on curated repositories of annotation knowl-
edge. Transformedmetadata is reviewed and reported to the
submitters for validation and approval. Once approved, the
transformed metadata describing a model is then loaded
into the PDX Finder database and exposed to the users
through the web interface.
One challenge inmetadata harmonization is themapping
of biologically identical histological concepts harboring dif-
ferent names provided by several sources using their own
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Figure 2. PDX Model and Patient Detail Pages. (A) Example of a PDX model detail page. A tabulated section beneath the overview provides summary
views of clinical, model and validation information. Contact links at the top right allow users to directly contact the PDXProducer for further collaboration.
(B) Example of a Patient Detail page that contains key clinical attributes about the tumor collection event(s) used to generate PDX models.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/D
1/D
1073/5232437 by Jackson Laboratory user on 14 January 2019
Nucleic Acids Research, 2019, Vol. 47, Database issue D1077
Figure 3. PDX Data pages. (A) The Molecular data page contains genomic data analysis files that where provided by the resources. A table summarises
the types of data and files accessible, with links to the datasets. The results can be exported in a tabular format using the ‘Download Results’ icon. (B) The
Drug dosing page summarise the drug-response results generated for a particular model. Links to protocols and platforms description are provided for all
datasets to allow the user to understand how the data was generated and analysed.
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classification. To harmonize those concepts and to support
consistent searching across the originating resources, we
sometimes aggregate histological term and primary tissue
attributes to achieve a more specific terminology. For exam-
ple, ‘Adenosquamous’, ‘adenosquamous carcinoma’, ‘Ad
and SC carcinoma’ all share the same primary tissue of ori-
gin ‘lung’ allowing mapping to the NCIT ontological term
‘Adenosquamous Lung Carcinoma’. Furthermore, onto-
logical association allows aggregation of concepts based on
meaningful groupings like cancer by anatomical system or
cell morphology. This allows users to search for ‘Lung Can-
cer’ models across all subclasses of Lung Cancer models in
a single query, without having to look for each subtype in-
dividually.
FUTURE DIRECTIONS
PDX Finder is a freely available global catalog of PDX
models and associated data available from independent, dis-
tributed repositories. Future development of PDX Finder
will focus on three areas: addition of new PDX repositories,
coordination with other informatics groups and implemen-
tation of user-requested functionality.
Adding new PDX repositories
Our primary focus in the near term is to increase the number
of PDX models represented in PDX Finder by contacting
individuals and organizations that maintain PDX reposito-
ries. To support scalability of data submission and process-
ing to PDX Finder, we have produced a data submission
template, available on request, that contains several mod-
ules based on our previously published PDX MI standard
and includes relevant examples to guide users. If imputing
PDX data via the template is not practical, we also pro-
vide a metadata checklist that can be used to develop direct
database exports (Supplementary Table S1). In addition to
metadata for models, we strongly encourage producers to
submit genomic datasets and information related to drug
dosing studies associated to their models submission to en-
hance the information we make discoverable for end users
through PDX Finder.
Coordination with other informatics resources
To facilitate data sustainability, maximize use of existing
data and avoid redundancy, the PDX Finder team has initi-
ated coordinating activities with existingmolecular archives
to deposit data generated fromPDXModels. The data load-
ing process can broker the submission of data to established
archives in collaboration with the data providers. Data
which access require application to a Data Access Commit-
tee approval will be submitted to relevant secure molecular
archives such as the European Genome-Phenome Archive
(9) or dbGAP (10).Depending on the data type, non-patient
identifiable datawill be submitted to other archive resources
including the Sequence Read Archive (11), the European
Nucleotide Archive (12) for nucleotide sequencing informa-
tion; Gene Expression Omnibus (13) or ArrayExpress (14)
for gene expression data or European Variation Archive
(https://www.ebi.ac.uk/eva/) for genetic variation informa-
tion. PDX Finder will also coordinate the submission of
sample metadata to BioSamples database (15), or BioSam-
ple archive (16), which provides unique identifiers that are
used to link varying types of data derived from the same
sample. Integration of the PDX Finder datasets linked to
their harmonized data inmolecular archives will ensure that
meta-analysis type of studies combine biologically compa-
rable datasets from multiple sources.
New functionality
Other areas of development will be determined by the needs
of the PDX research community. We will continue to as-
sess user needs by surveys and testing of the portal. As the
number of informatics resources using PDX models grows,
the community is best served by sharing solutions to com-
mon challenges. The PDXFinder team is committed to con-
tributing to a data science environment of collaborative de-
velopment and reuse of informatics tools. In planning the
implementation of new functionality and user interfaces,
the PDX Finder team first evaluates software developed by
other groups to address common needs. For example, we are
coordinating with several resources funded by NCI’s Infor-
mation Technology for Cancer Research (ITCR) program,
including cBioPortal for cancer genomic data visualisation
(17) and the CIViC Database for clinically relevant anno-
tation of cancer variants (18). In addition to leveraging ex-
ternal bioinformatics resources to enhance functionality of
PDX Finder, our team is providing critical software com-
ponents to support the PDXNet and the EurOPDX data
platforms.
Future versions of the PDX Finder will capture addi-
tional attributes and ‘omics’ datasets. Given the recent suc-
cess of immune checkpoint inhibitors in the treatment of
cancer, ‘humanized immune system’ PDX models have a
key role in immuno-oncology drug validation, so their ac-
curate representation will need to contain additional at-
tributes such as HLA status of the tumor and the donor
of human cells. We are monitoring advances with special-
ists in the field and PDX Finder will capture those models
as standard approaches in their generation and use emerge.
COMMUNITY OUTREACH AND USER SUPPORT
The PDX Finder user help desk is available via email and
user outreach is supported through Twitter and the PDX
Finder News and Event section on the homepage. Re-
searchers interested in listing their PDX repository in PDX
Finder should contact the team using the submission email
provided below. A checklist of the data we collect is in-
cluded in Supplementary Table S1. The PDX Finder team
will work directly with data providers to ensure their PDX
models are represented accurately.
• PDXdata submission email: submissions@pdxfinder.org
• Twitter: https://twitter.com/PDXFinder
CITING PDX FINDER
For a general citation of PDX Finder, researchers should
cite this article. In addition, the following citation for-
mat is suggested when referring to specific data about
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PDX models obtained from the PDX Finder web site:
PDX Finder (http://www.pdxfinder.org); data retrieved in
September 2018.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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